FY2026 · ended Jan 3, 2026 · Revenue $52.67M, +8.2% YoY · Filed Apr 2, 2026
Iridex Corp (IRIX) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. In fiscal 2026, which ended Jan 3, 2026, it reported revenue of $52.7 million and a net loss of $4.4 million. Free cash flow was -$2.3 million. As of Jul 4, 2026 it held $4.7 million in cash and investments and $218,000 in total debt.
Revenue
$52.67M
+8.2% vs prior year
Net income
$-4.44M
+50.2% vs prior year
Operating cash flow
$-2.12M
+71.0% vs prior year
Free cash flow
$-2.26M
+69.1% vs prior year
EPS
$-0.26
+51.9% vs prior year
Dividend per share
None
Shares outstanding
17.31M
+3.1% vs prior year
Net cash
$4.46M
as of Jul 4, 2026
Operating margin
-4.9%
FY 2026
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- IRIX (Nasdaq)
- Fiscal year ends
- January 3
- Incorporated in
- DE
- Headquarters
- Mountain View, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1006045
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jan 3, 2026 |
FY 2024 Dec 28, 2024 |
FY 2023 Dec 30, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Jan 1, 2022 |
|---|---|---|---|---|---|
| Revenue | $52.7M | $48.7M | $51.9M | $57.0M | $53.9M |
| Operating income | -$2.6M | -$8.3M | -$10.0M | -$7.5M | -$7.5M |
| Net income | -$4.4M | -$8.9M | -$9.6M | -$7.5M | -$5.2M |
| Diluted EPS | -$0.26 | -$0.54 | -$0.59 | -$0.47 | -$0.34 |
| Operating cash flow | -$2.1M | -$7.3M | -$6.7M | -$9.5M | $8.2M |
| Free cash flow | -$2.3M | -$7.3M | -$6.9M | -$9.8M | $8.0M |
| Total assets | $29.2M | $29.1M | $34.4M | $42.3M | $48.7M |
| Total liabilities | $24.2M | $27.0M | $24.9M | $25.1M | $25.4M |
| Stockholders' equity | $4.9M | $2.1M | $9.5M | $17.2M | $23.3M |
| Cash and investments | $6.0M | $2.4M | $7.0M | $13.9M | $23.9M |
| Total debt | $797,000 | $4.6M | $2.7M | $1.8M | $2.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Sep 2, 2026 | Aug 27, 2026 |
| 10-Q | Quarterly report | Aug 18, 2026 | Jul 4, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 18, 2026 | Aug 18, 2026 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Jul 16, 2026 | Jul 10, 2026 |
| 8-K |
Current report
Other events
|
Jun 18, 2026 | Jun 12, 2026 |
| 10-Q | Quarterly report | May 19, 2026 | Apr 4, 2026 |
All 1000 Iridex Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.